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Abstract
The aim of this study was to evaluate the transdermal delivery of two meloxicam salts, meloxicam sodium and meloxicam
potassium, enhanced by iontophoresis and/or electroporation in vitro with Wistar rat dorsal skin and human epidermal membrane
(HEM) as barriers and in vivo with Wistar rat as the animal model. Iontophoresis and its combination with electroporation could significantly enhance the in vitro permeation of both salts, and two protocols had the same enhancement to each salt. Furthermore, the
combination protocol had more enhancement to potassium salt than sodium salt. Interspecies difference was found in some electrical
protocols. Electroporation might depress the transdermal delivery of meloxicam sodium while it might enhance that of meloxicam
potassium. Iontophoresis, electroporation and their combination could increase the delivery of the two salts and result in significantly
higher AUC of drug concentration to time in vivo. It was concluded that the in vitro and in vivo transdermal delivery of meloxicam
potassium was more facilitated by the combination protocol than meloxicam sodium.
Key words: transdermal delivery, meloxicam salts, iontophoresis, electroporation

Introduction
Meloxicam is a non-steroidal anti-inflammatory drug
(NSAID) of the acidic enolcarboxamide class. Meloxicam
has faster anti-inflammatory and anti-arthritic activities as
compared to piroxicam, indomethacin, diclofenac, tenoxicam, naproxen and aspirin after oral administration(1).
Another administration route, transdermal transport, has been shown to deliver the meloxicam successfully(2,3). According to our previous study, iontophoresis
could enhance the delivery of three salts of diclofenac (4,5),
and this result led us to study the transdermal delivery
of meloxicam salts by two physical enhancers, namely
iontophoresis and electroporation.
Iontophoresis can enhance the transdermal delivery
of compounds like drugs and peptides, and the synergistic
effect of iontophoresis combined with electroporation has
been reported in many studies. Several factors have been
demonstrated to influence the transdermal permeation of
drug molecules by iontophoresis or electroporation(6-8);
however, the influence of combination strategy of iontophoresis and electroporation on the transdermal delivery
of various salts of one drug has rarely been discussed.
* Author for correspondence. Tel: +886-7-3121101 ext. 2166;
Fax: +886-7-3210683; E-mail: yhtsai@kmu.edu.tw

This study was aimed to evaluate the enhancement
of iontophoresis, electroporation and a combination protocol on the transdermal delivery of two meloxicam salts,
meloxicam sodium and meloxicam potassium, as model
drugs in vitro and in vivo. Human epidermal membrane
and Wistar rat dorsal skin were used as barriers in vitro to
examine the influence of the two physical enhancers and
inter-species difference. The pharmacokinetics was also
evaluated in vivo with Wistar rat as the animal model.

Materials and methods
I. Materials and Barriers
Two meloxicam salts, meloxicam sodium and
meloxicam potassium, were custom-synthesized as
follows: 10 g meloxicam was added into 1.2 L dichloromethane and the mixture was stirred for 5 min. Two and
half liter of de-ionized water containing 20 g of NaOH/
KOH was added into the solution and allowed to react for
at least 6 hr. Afterwards, the water layer was heat-dried,
and the residue was filtered and washed with sufficient
dichloromethane and de-ionized water. The product was
desiccated in the vacuum oven until the residual solvent
vaporized. Two products of meloxicam salts were veri-
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fied by GC/MS (JMS-700, JEOL, Japan) with FAB (fast
atom bombardment), and it confirmed that the two salts
were successfully synthesized.
In vitro permeation experiments were performed
using the human epidermal membrane and the full and
shaved rat skin removed from the back region of the male
Wistar rat (6 ~ 8 weeks old). Human skin from the breast
after breast reduction operation was supplied by ChungHo Memorial Hospital of Kaohsiung Medical University
and its epidermal membrane was prepared by heat separation method (9). All chemicals and solvents were of
analytical grade.
II. Determination of Partition Coefficient
The partition coefficient was measured in n-octanol/buffer (v/v, 1:1). The n-octanol was saturated with 60
mM citrate-phosphate buffer (pH = 7.4) overnight before
the partition measurement. Both saturated n-octanol and
buffer containing meloxicam salt were added into the
capped glass tube which was then horizontally shaken for
24 hr. After mixing well, the buffer layer was analyzed
by HPLC. The partition coefficient was calculated as the
ratio of the drug concentration in the n-octanol phase to
that in the buffer.
III. In Vitro Permeation Experiments
Modified horizontal glass diffusion cells with an
intercept area of 0.785 cm 2 were utilized in the in vitro
permeation experiments. The skin was mounted between
the two half horizontal cells. The donor compartment of
the cell was filled with 8 mL of 60 mM citrate-phosphate
buffer (pH 6.08) containing 12.5 mM meloxicam salt and
the receptor phase contained 8 mL of 60 mM citratephosphate buffer (pH 7.4). Each cell was maintained at
37°C in a water jacket and agitated with a magnetic stirrer at 600 rpm. Sample (0.2 mL) was withdrawn from
the receptor component at regular intervals and replaced
by an equal volume of fresh buffer solution immediately.
All samples were then analyzed by HPLC.
IV. Iontophoresis and Electroporation Protocols
An exponential decay pulse generator (ECM 630
Electro Cell Manipulator, BTX Co., USA) was used to
perform the electroporation. A pair of platinum electrodes (0.5 × 1.5 cm 2) were used and each was located
3 cm from the skin. The cathode was positioned in the
donor site and the anode in the receptor site. The electroporation protocol was 1 pulse per 30 sec, applied for 10
min; the pulse voltage was set at 300 V and pulse duration was about 200 ms. The voltage was expressed as an
applied value but not as a transdermal value. A direct
current power supply (Model 7651, Yokogawa Electrical Co., Japan) connected with a pair of platinum wires
(0.5 mm diameter) was used in the in vitro permeation

experiments. An effective length of 15 mm of platinum
wire was immersed in the buffer as electrodes, with cathode in the donor site and anode in the receptor site. The
electrodes were positioned 3 cm away from each side of
the skin or membrane. The current density was set at 0.5
mA/cm 2. The iontophoresis was applied continuously
and the application time was set at 3 hr. The combination protocol was consisted of 10 min of electroporation
following by 3 hr of iontophoresis.
V. In Vivo Transdermal Study
Male Wistar rat (180 ~ 200 g) was anesthetized by
intraperitoneal injection of 25% urethane at a dose of 3
mL/kg and the back fur of the rat was shaved. Two glass
cylinders each with the available diffusion area of 1.539
cm 2 were placed above the dorsal skin with glue (Super
Glue Gel®, 3M, USA). An aliquot of 2 mL of citratephosphate buffer (pH 6.08) containing 12.5 mM meloxicam salt was added into the donor (cathode-containing
cylinder), while the receptor was filled with 2 mL of
citrate-phosphate buffer (pH 7.4). The platinum plates
were put in the center of the cylinders and vertical to the
skin. The pair of platinum wires was bent to be horizontal to the skin and parallel to each other. After the
electrical protocol started, about 0.3 ~ 0.4 mL of blood
was withdrawn from the carotid at one hour interval. All
samples were analyzed by HPLC. The animal experiment
was reviewed and approved by the Institutional Animal
Care Committee at Kaohsiung Medical University.
VI. Sample Analysis
The analytic method, HPLC, was modified from our
previous study(3). In vitro samples of meloxicam were
acidified with aliquots of 1N HCl and prioxicam was
added as internal standard for HPLC analysis. In vivo
plasma samples were also supplemented by 1N HCl and
prioxicam, and then extracted with dichloromethane.
The organic layer of each sample was vacuum vaporized
and re-dissolved with the mobile phase of HPLC. The
HPLC system of Waters LC Module 1 with a C18 column
(LichroCart ® 125-4, Merck) as the stationary phase was
employed. The mobile phase consisted of 40% methanol,
10% acetonitrile and 50% aqueous solution with 50 mM
di-ammoniumhydrogenphosphate, pH = 7, at a flow rate
of 1 mL/min. The wavelength of the UV detector was set
at 363 nm. The in vitro calibration curves were linear (R 2
> 0.998 for sodium salt and R 2 > 0.999 for potassium salt)
over the concentration range of 0.5 ~ 50 µg/mL (6 points,
n = 6). The intraday coefficients of variation were less
than 4.7% and 3.7% for sodium salt and potassium salt,
respectively. The in vivo calibration curves were linear
(R 2 > 0.999 for sodium and R 2 > 0.995 for potassium salt)
over 0.5 ~ 50 µg/mL (6 points, n = 6). The intraday coefficients of variation were less than 4.9% for sodium and
12% for potassium salt.
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VII. Data Analysis
The cumulative amount of drug permeating into the
receptor through the unit diffusion area was calculated
and plotted as a function of time. Values of the flux at the
first 3 hr interval were analyzed. Penetration index (PI)
was calculated from the ratio of cumulative amount of
electrically-assisted method to that of passive control. The
Student’s t-test and one-way ANOVA were utilized to test
the various treatment effects. Subgroup comparisons were
made using the Newman-Keuls multiple comparisons.
The level of significance in all tests was set at 0.05.

Results
I. In Vitro Permeation Experiments
(I) Wistar Rat Skin as the Barrier
The passive transport of meloxicam sodium through
Wistar rat skin was shown in Table 1. The 3 and 12 hr
cumulative amount of meloxicam sodium via passive

transport was higher than that of meloxicam potassium
(t-test, p < 0.05). The flux of the first 3 hr of meloxicam
sodium was almost 10 times higher than that of meloxicam potassium.
The results of meloxicam sodium permeation through
Wistar rat skin and enhanced by iontophoresis / electroporation are presented in Figure 1A. During 12 hr of
transdermal transport, electroporation did not enhance the
permeation of meloxicam sodium in terms of both 3 hr and
12 hr cumulative amount (ANOVA test, p > 0.05). Moreover, in terms of PI, electroporation seemed to retard the
permeation of meloxicam sodium through Wistar rat skin;
on the other hand iontophoresis resulted in 11.26-fold of
3 hr cumulative amount and 19.56-fold of 12 hr cumulative amount, respectively, when compared with those of
passive controls. Meloxicam sodium could benefit from
the combination of electroporation and iontophoresis
which resulted in 3 hr PI of 12.86 and 12 hr PI of 22.13
(ANOVA test, p < 0.05). However, the enhancement of
electroporation/iontophoresis seemed the same as that of
iontophoresis since there was no significant difference in
terms of 3 hr and 12 hr cumulative amount, respectively.
Surprisingly, as shown as Table 1 and Figure 1B, the

Table 1. The in vitro transdermal permeation profiles of meloxicam sodium and meloxicam potassium delivered by electrically-assisted
methods across Wistar rat dorsal skin and HEM
Skin types

Model drugs

Meloxicam
sodium
Wistar rat
dorsal skin
Meloxicam
potassium

Meloxicam
sodium
HEM
Meloxicam
potassium

Methods

3 hr CAa
(nmol/cm2)

3 hr PI

Passive

29.78 ± 2.47βθ*

–

ITP

335.44 ± 130.76αγ

EP

2.53 ± 2.52βθ*
αγ

EP+ITP

383.02 ± 117.30

Passive

2.83 ± 3.10βθ*

ITP

320.20 ± 57.14αγ

12 hr CA
(nmol/cm2)

12 hr PI

0~3 hr flux
(nmol/cm2/hr)

44.73 ± 22.02βθ*

–

7.07 ± 0.79βθ*

11.26

875.04 ± 246.44αγ

19.56

112.75 ± 44.64αγ

0.08

36.14 ± 28.60βθ*

0.81

0.55 ± 0.55βθ*

12.86

αγ

22.13

126.79 ± 38.62αγ

989.69 ± 303.58

–

7.00 ± 2.98βθ*

–

0.75 ± 0.74βθ*

113.01

980.84 ± 174.30αγ

140.13

106.95 ± 17.94αγ

EP

66.40 ± 18.20βθ*

23.43

243.11 ± 89.98βθ*

34.45

21.42 ± 7.36βθ*

EP+ITP

407.00 ± 119.24αγ

143.64

1157.71 ± 326.55αγ

165.39

133.90 ± 37.70αγ

Passive

31.55 ± 24.74βθ

–

33.16 ± 25.01βθ

–

ITP

189.33 ± 67.60αγ

8.82

211.54 ± 76.78αγ

9.32

64.23 ± 24.13αγ

EP

0.52 ± 0.47βθ*

0.02

2.35 ± 1.25βθ

0.10

0.15 ± 0.19βθ

EP+ITP

122.23 ± 58.56αγ*

5.70

159.31 ± 49.92αγ*

7.02

41.15 ± 22.38αγ

Passive

5.80 ± 4.71βθ

ITP

αγ

196.09 ± 38.68

–
33.79

7.58 ± 6.90βθ

–

8.87 ± 0.01βθ*

1.57 ± 2.11βθ*

αγ

30.49

67.84 ± 13.65αγ

231.24 ± 35.31

EP

48.82 ± 29.54βθ*

8.41

83.74 ± 62.98βθ

11.04

15.67 ± 11.52βθ

EP+ITP

252.72 ± 82.77αγ*

43.55

306.01 ± 98.38αγ*

40.34

82.73 ± 26.97αγ

Each value represents the mean ± S.D. (n = 4).
α,β,γ,θ
Data of one skin type and model drug were analyzed by ANOVA followed by Newman-Keuls test (significant level = 0.05).
α
significantly different from passive; βsignificantly different from ITP; γsignificantly different from EP;
θ
significantly different from EP+ITP.
* Data of two model drugs with the same skin type and method were significantly different from each other (t-test, p < 0.05).
CA: cumulative amount; ITP: iontophoresis; EP: electroporation.
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Figure 1. Cumulative amount versus time profile of (A) meloxicam sodium and (B) meloxicam potassium and enhanced by electrically assisted
methods through Wistar rat skin. All data represent the means of the experiments ± S.D. (n = 4). ITP, iontophoresis; EP, electroporation.
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Figure 2. Cumulative amount versus time profile of (A) meloxicam sodium and (B) meloxicam potassium and enhanced by electrically assisted
methods through HEM. All data represent the means of the experiments ± S.D. (n = 4). ITP, iontophoresis; EP, electroporation.

3 hr and 12 hr cumulative amounts of meloxicam potassium were both enhanced by electroporation by 23.43 and
34.45-fold when compared to those of passive control,
respectively. Both the 3 hr and 12 hr PI of meloxicam
potassium permeated through Wistar rat skin by electroporation were also higher than that of meloxicam sodium
(t-test, p < 0.05), respectively.
Iontophoresis significantly enhanced the transport of
meloxicam potassium through Wistar rat skin in terms of 3
hr cumulative amount (ANOVA test, p < 0.05). Moreover,
at post-iontophoresis period (3 ~ 12 hr), the enhancing
effect remained thus resulting in a significant enhancement
of 12 hr cumulative amount. The 3 hr and 12 hr cumulative amounts of meloxicam potassium transported through
Wistar rat skin enhanced by iontophoresis were similar to
those of meloxicam sodium; however, both the 3 hr PI and
12 hr PI of meloxicam potassium were higher than those of
meloxicam sodium. This phenomenon was due to a lower

passive transdermal amount of meloxicam potassium than
that of meloxicam sodium. (t-test for 3 hr and 12 hr cumulative amount, respectively, p < 0.05).
After 10 min of electroporation and 3 hr of iontophoresis, 3 hr cumulative amount of meloxicam sodium
permeated through Wistar skin rat skin was similar to
that enhanced by iontophoresis alone (ANOVA test,
p > 0.05). This result was also found after 12 hr. The
phenomenon was also found in the transdermal permeation of meloxicam potassium. It seemed that there was
no synergistic effect of electroporation/iontophoresis in
the enhancement of the two meloxicam salts permeated
through Wistar rat skin.
(II) HEM as the Barrier
The result of passive permeation of meloxicam sodium
through HEM was shown in Table 1 and Figure 2A. It was
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Figure 3. (A) meloxicam sodium and (B) meloxicam potassium concentration in plasma by treating electrically assisted methods with Wistar
rat as an animal model. All data represent the means of the experiments ± S.D. (n = 4). ITP, iontophoresis; EP, electroporation.

observed that 3 hr cumulative amount of passive permeation was similar to that through Wistar rat skin (t-test, p
> 0.05). After the application of iontophoresis, 3 hr and
12 hr PI were 8.82 and 9.32, respectively, and the enhancement was less than that of meloxicam sodium through
Wistar rat skin. Electroporation, as discussed above, was
found to reduce the transport of meloxicam sodium. Electroporation/iontophoresis could result in 3 hr PI of 5.70 and
12 hr PI of 7.02, and both were lower than those by iontophoresis. However, 3 hr cumulative amount of meloxicam
sodium enhanced by electroporation/iontophoresis through
HEM was similar to that enhanced by iontophoresis alone
(ANOVA test, p > 0.05). The same was also found in 12 hr
cumulative amount.
The cumulative amount of meloxicam potassium due
to passive diffusion through HEM was lower than that of
meloxicam sodium, but it showed no significant difference due to the variability of human skin. Iontophoresis
greatly enhanced the cumulative amount of meloxicam
potassium through HEM in terms of 3 hr PI of 33.79 and
12 hr PI of 30.49, even after iontophoresis ceased. When
compared to the result of meloxicam sodium, electroporation produced higher 3 hr PI and 12 hr PI of meloxicam
potassium. As the result of iontophoresis, electroporation/iontophoresis could enhance the transdermal permeation of meloxicam potassium in terms of 3 hr cumulative
amount and 12 hr cumulative amount.
II. In Vivo Permeation Experiments
The plasma concentration-time curves of meloxicam
salts after transdermal application of electrical enhancement are shown in Figure 3. Not only iontophoresis and
combination protocol but also electroporation alone could
significantly enhance the in vivo permeation of meloxicam sodium and meloxicam potassium when compared
with the passive control in terms of 3 hr AUC, 12 hr AUC

and Cmax (ANOVA test, p < 0.05), as shown in Table 2.
Combination protocol further enhanced the permeation
of meloxicam salts and resulted in higher 3 hr AUC than
electroporation did (ANOVA, p < 0.05). This phenomenon could also be found in 12 hr AUC of meloxicam
potassium, but not in meloxicam sodium. Iontophoresis,
however, resulted in the same enhancement with electroporation on potassium salt in terms of 3 hr and 12 hr
AUC. It was also found that the combination protocol
resulted in higher Cmax of meloxicam potassium than that
of meloxicam sodium (t-test, p < 0.05), while individual
protocol had the same effect on both salts.

Discussion
I. In Vitro Permeation Experiments
(I) The Effect of Electroporation
Iontophoresis is usually accompanied by electroporation, which can disorder the lipid bilayers of the skin
and create new pathways into the skin and allow charged
or neutral molecules transport through not only the
subsistent appendageal pathway but also the new aqueous
pathway under electric-field or by passive diffusion, thus
resulting in enhanced transdermal transport (7). Two skin
barriers including the dorsal site of male Wistar rat skin
and human epidermal membrane of breast site were used
in vitro to elucidate the possible transdermal behavior of
the sodium salt and potassium salt of meloxicam.
From the results mentioned above, it was found
that the PIs of meloxicam potassium permeated through
Wistar rat skin and HEM were generally higher than that
of meloxicam sodium. The difference of transdermal
behavior could be seen from the result of passive diffusion (t-test, p < 0.05). The electroporation, however,
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Table 2. Parameters of the in vivo transdermal permeation of meloxicam sodium and meloxicam potassium enhanced by electrically-assisted
methods with Wistar rat as an amimal model
Model drugs

Methods
Passive

Meloxicam sodium

ITP
EP
EP+ITP
Passive

Meloxicam potassium

0~3 hr AUC
βγθ

0

0~12 hr AUC
0

0

αγ

46.67 ± 14.44

αβθ

α

11.28 ± 3.42
5.42 ± 0.66

αγ

11.97 ± 1.15

βγθ

0.09 ± 0.01

Cmax (µg/mL)

βγθ
α

41.26 ± 7.21

α

57.51 ± 10.42

βγθ

1.87 ± 0.14

tmax (hr)

βγθ

NA
α

9.25 ± 3.4

α

11 ± 1

α*

9±3

4.33 ± 1.59
5.10 ± 1.05
5.95 ± 0.98

βγθ

1.57 ± 0.10

12 ± 0

ITP

7.75 ± 4.54α

56.42 ± 26.96α

6.07 ± 2.53α

9 ± 5.2

EP

4.61 ± 1.68αθ

38.04 ± 15.42αθ

7.14 ± 3.43α

11.75 ± 0.5

EP+ITP

αγ,

12.13 ± 3.01

αγ

73.24 ± 8.87

α*

9.23 ± 1.86

11 ± 1.41

Each value represents the mean ± S.D. (n = 4).
αβγθ
Data of one skin type and model drug were analyzed by ANOVA followed by Newman-Keuls test (significant level = 0.05).
α
Significantly different from passive; βsignificantly different from ITP; γsignificantly different from EP;
θ
significantly different from EP+ITP.
*Data of two model drugs with the same skin type and method were significantly different from each other (t-test, p < 0.05).
AUC: area under curve; ITP: iontophoresis; EP: electroporation; NA: not available.

might retard the transdermal permeation of meloxicam
sodium since the PI was below zero. Instead, the 3hr
and 12hr cumulative amounts of meloxicam potassium
through Wistar rat skin and 3hr cumulative amount of
meloxicam potassium through HEM were significantly
higher than those of meloxicam sodium, respectively (ttest, p < 0.05). This indicated that meloxicam potassium
could benefit from the enhancement of electroporation.
Several physicochemical properties of the drugs,
including charge, molecular weight, conformation and
lipophilicity, could influence the drugs transport by
electroporation(7). Also, the mechanism, namely electrophoretic movement, diffusion and electroosmosis, of
enhancement by electroporation should be considered.
Meloxicam has a pKa of about 4.08 and almost ionized in
citrate-phosphate buffer of pH 6.08. It has been suggested that the counter-ion in the formulation can influence
the passive and iontophoretic permeation of the drug;
however, the mechanism of how the counter-ion affects
the permeation by electroporation remains unclear.
Since the charge, M.W. and conformation of meloxicam
sodium were similar to that of meloxicam potassium, the
lipophilicity of the two salts was measured. The result
showed that the partition coefficients (citrate-phosphate
buffer, pH = 6.08/octanol) of meloxicam sodium and
meloxicam potassium were 7.60 and 7.92, respectively,
and the difference could merely explain the effect of
electroporation on meloxicam sodium and meloxicam
potassium. Further more, the protocol of electroporation applied in the study was 20 pulses within 10 min;
hence the contribution of electrophoretic movement and
electroosmosis could be negligible to molecules with low
molecular weight like meloxicam sodium and meloxicam
potassium. The enhancement of electroporation could be
mainly due to the passive diffusion of meloxicam sodium

and meloxicam potassium through the new pathway
created by electroporation. According to the previous
study, extraneous ions could influence the transdermal
iontophoretic delivery of hydromorphone (10). After the
electrotransport of hydromorphone with a monovalent
(Li+) or a divalent cation (Ca+2), the authors concluded
that the difference of permeation behavior may result
from the presence of more than one type of aqueous pathway or it may be due to differences in binding affinity of
lithium and calcium to the charged sites within the pathway. However, we also observed this phenomenon in the
presence of original and new pathways and two cations
with equal valence. Since the transportation of the drug
ion is in the form of ion-pair (10), our hypothesis was that
the retention of hydrated sodium ion rather than potassium ion in the new pathways created by electroporation
resulted in slower permeation of the meloxicam ion, and
this result appeared to agree with the hypothesis of binding affinity.
(II) Inter-species Difference
In spite of the technologies of enhancement, the two
salts showed different transdermal behavior in different barriers. It was reported that iontophoresis could
reduce inter-species difference (11,12). Our previous study
showed that not only iontophoresis but also the combination of iontophoresis and electroporation could reduce
interspecies difference in terms of flux and cumulative
amount (13). However, in some cases of both salts, iontophoresis and the combination protocol resulted in greater
3 hr and 12 hr cumulative amounts and 3 hr flux when
permeating through Wistar rat skin than that through
HEM (t-test, p < 0.05). Also, electroporation induced
higher 12 hr cumulative amount of potassium salt perme-
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ated through Wistar rat skin than that through HEM.
This result suggested that the transdermal behavior of
meloxicam sodium and meloxicam potassium through
HEM was different from that through Wistar rat skin
when enhanced by electrical protocols.
(III) The Synergistic Effect of Electroporation/Iontophoresis
A common strategy, the combination of iontophoresis and electroporation, was performed to produce synergistic effect on the enhancement of transdermal permeation. The synergistic effect was examined in this study.
It was found that the enhancement of electroporation/
iontophoresis of meloxicam sodium or meloxicam potassium respectively through Wistar rat skin was not significantly different from that of iontophoresis (ANOVA test,
p > 0.05), and the same phenomenon was also found in
two salts permeated through HEM. This indicated that
electroporation/iontophoresis had no synergistic effect
compared to iontophoresis alone on the enhancement of
the transdermal delivery of the two meloxicam salts.
With the enhancement of the combination of electroporation/iontophoresis, meloxicam potassium seemed
to be more facilitated than meloxicam sodium. The 3
hr and 12 hr cumulative amounts meloxicam potassium
permeated through HEM and enhanced by combination
protocol were significantly higher than that of meloxicam
sodium (t-test, p < 0.05), but this result was not found in
Wistar rat skin, which suggested that meloxicam potassium might have more advantage than meloxicam not only
in oral administration but also in transdermal delivery
enhanced by electrical protocols.
II. In Vivo Permeation Experiments
The synergistic effect of the combination of iontophoresis and electroporation was hardly found in the
transdermal permeation of meloxicam salts. However,
Our previous study demonstrated that the combination
protocol could resulted in synergistic effect of enhancement of the in vivo transdermal permeation of indomethacin(13). It was also found that electroporation alone could
result in the same level of enhancement of iontophoresis
and the combination protocol on meloxicam sodium in
terms of 12 hr AUC (ANOVA test, p > 0.05). Although
combination protocol had the same effect on both meloxicam salts in terms of 3 hr and 12 hr AUC (t-test, p >
0.05), it resulted in higher Cmax of potassium salt than
that of sodium salt (t-test, p < 0.05). After the electrical protocols ceased, the concentration of potassium salt
remained increasing, but not for sodium salt especially
when enhanced by iontophoresis. The result indicated
that meloxicam potassium might have more advantages
than meloxicam sodium. The in vivo enhancement of
electroporation was discrepant to that of in vitro study
and further study is needed.

Conclusions
The present study established the iontophoretic and
electroporatic properties of meloxicam salts through the
transdermal experiments. Iontophoresis and the combination protocol enhanced the in vitro skin permeation of
meloxicam sodium and meloxicam potassium and resulted
in greater permeation than electroporation did, but there
was also interspecies difference. Electroporation did not
produce a synergistic enhancing effect when combined
with iontophoresis in vitro. The in vitro transdermal
permeation of meloxicam sodium might be depressed by
electroporation while meloxicam potassium might profit
from it, but this result was not found in vivo. Meloxicam
potassium gained more from the combination of electroporation/iontophoresis than meloxicam sodium in vitro.
Both meloxicam salts could benefit from iontophoresis,
electroporation and the combination protocol, and meloxicam potassium might take more advantages from the
combination protocol than meloxicam sodium in vivo.
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